STOK STOKE THERAPEUTICS INC Expansion Plans 8-K Filing 2025 - Product Expansion On June 4, 2025, Stoke Therapeutics, Inc. updated its corporate presentation regarding the initiation of its Phase 3 EMPEROR study for zorevunersen, with U.S. sites initiated in May 2025.Get access to all SEC 8-K filings of the STOKE THERAPEUTICS INC